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Figure 1. K-M probability of grade II-IV and III-IV acute GVHD
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in combination with tacrolimus for acute GVHD prophylaxis
in 39 children and young adult AlloSCT recipients.
Methods: GVHD prophylaxis consisted of tacrolimus 0.03-
0.04 mg/kg/day IVCI on Day -1 or 1st day of conditioning
(target range 10-20 ng/mL) and MMF 900 mg/m2 (max 1.5 g/
dose) or 15 mg/kg (age  18 y or weight  70 kg, max 1.5 g/
dose) IV/PO q8h starting on Day +1. Patients were changed to
PO tacrolimus (1:4 dose conversion IV:PO) as clinically
appropriate post-AlloSCT. GVHD prophylaxis was continued
until Day +180 followed by a taper in patients with non-
malignant disorders. In patients with malignant disorders,
MMF was discontinued on Day +30 or Day +60, followed by a
slow tacrolimus taper starting on Day +60. Mycophenolic
acid (MPA) trough concentrations were obtained if MMF-
induced toxicity was suspected. AGVHD, chronic GVHD
(cGVHD) and overall survival (OS) were determined by
Kaplan-Meier (K-M) method.
Results: 39 patients (mean age 12 years [range 0.1-23.5
years]; 27 male vs 12 female) received myeloablative
(n¼20) and non-myeloablative (n¼19) conditioning for
malignant (n¼28) and non-malignant disorders (n¼11).
Donor sources were: 6/6 MSD (n¼12), 4/6-6/6 UCB
(n¼16), and 9/10 or 10/10 MUD (n¼11). Sixteen/28 pa-
tients with malignant disease were poor risk. Median time
to myeloid and platelet engraftment was 16 and 32 days,
respectively. Probability of grade II-IV aGVHD and grade
III-IV aGVHD was 16.6% (CI95: 1.8-44.7) and 2.9% (CI95: 0-
60.6), respectively (n¼37 evaluable patients).[Figure 1]
Only one patient experienced grade III (liver +gut) aGVHD,
with no patients developing grade IV aGVHD. Probability
of limited + extensive cGVHD (n¼34 evaluable patients)
was 23.6% (CI95: 8.0-50.5).
Nine patients died at a median 198 days post-SCT
(range 109-549). Causes of death included chronic GVHD
(n¼2), acute GVHD (n¼1), TMA (n¼1), viral or fungal
infection (n¼2), relapse (n¼2), and EBV PTLD (n¼1). K-M
probability of 1 year overall survival was 72.5% (CI95: 53.3-
84.9).
Conclusion: Tacrolimus in combinationwith MMF given q8h
as described above are highly effective for aGVHD prophy-
laxis in this heterogeneous group of pediatric and young
adult AlloSCT recipients. The incidence of grade II-IV aGVHD
in the current study appears to be substantially lower than
reported in our previous trial withMMF dosed at 900mg/m2
q6h in a similar group of pediatric and adolescent AlloSCT
recipients (16.6% vs 54.4%).[Bhatia/Cairo et al. BBMT
2010;16(3):333-343]544
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The National Marrow Donor Program (NMDP) has estimated
that the number of hematopoietic stem cell transplants
(HSCTs) performed will double by 2015 as compared to 2010.
The NMDP also projects a shortage of physicians, physician
assistants, nurses, nurse practitioners, and pharmacists. In
response to this anticipated shortage, the American Society
for Blood and Marrow Transplantation (ASBMT) Pharmacy
Special Interest Group (SIG) was created in 2012. The ASBMT
Pharmacy SIG recognized the need to engage non-physician
providers in the care of patients and supplement the training
of such practitioners. The ASBMT Pharmacy SIG has priori-
tized the education of these practitioners and has success-
fully developed and implemented the Fundamentals of HSCT
course to address this issue.
Another priority of the ASBMT Pharmacy SIG was to
determine the value of HSCT pharmacists in clinical
practice. Thus, a survey was conducted in January 2014
to collect baseline data of the current ASBMT Pharmacy
SIG make-up and practice patterns. The survey was
distributed to approximately 250 participants and 56
surveys were returned. Of the 56 responders, most
practitioners worked in academic medical centers (91%)
with the majority of centers performing less than 300
HSCTs per year (85%). Most institutions had 3 or fewer
pharmacists dedicated to HSCT services (68%). The
highest level of training and certiﬁcation for the majority
of pharmacists practicing in HSCT was a post-graduate
year 2 oncology pharmacy practice residency (64%) and a
board certiﬁcation in oncology pharmacy (61%), respec-
tively. Though the majority of practitioners spent any-
where from 50-100% of their time dedicated to clinical
activities, only 25% of practitioners had an established
collaborative practice protocol in place. Furthermore,
most HSCT pharmacists spent 20% or less of their time
devoted to teaching, administrative, or research activ-
ities. Many practitioners were involved with pharmacy
organizations and spent time outside of their clinical
duties to work on publications and professional
development.
The results of this survey provide a snapshot of the cur-
rent HSCT pharmacy climate and may be used as a tool to
educate healthcare practitioners on roles and re-
sponsibilities of HSCT pharmacists. These results may also
serve as foundation for the development of HSCT phar-
macist competencies in the future and a framework for
Abstracts / Biol Blood Marrow Transplant 21 (2015) S355eS373 S371future analyses, such as determination of value of services,
which in turn could support the justiﬁcation of HSCT
pharmacy services.545
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Background: Sulfamethoxazole/trimethoprim (SMX/TMP) is
the current gold standard for PCP prophylaxis in hemato-
poietic stem cell transplant (HSCT) patients. There are
several second line options for prophylaxis but many,
including intravenous (IV) pentamidine, have not been
proven to be as effective or as safe as SMX/TMP in the pe-
diatric HSCT population. There is increasing use of IV pen-
tamidine in the pediatric HSCT population, as it is easily
given once monthly, with no issues regarding compliance or
vomiting. However, there are limited published data to
support safety and efﬁcacy of this approach. This study was
aimed to determine the safety and efﬁcacy of IV pentamidine
in preventing PCP infection in our pediatric HSCT patients.
Methods: A retrospective chart review was conducted with
IRB approval to evaluate all HSCT patients at Cincinnati
Children’s Hospital Medical Center (CCHMC) that received at
least one dose of IV pentamidine from January 2010 to July
2013. The primary outcome, pentamidine efﬁcacy, was
evaluated through lack of breakthrough PCP infection. The
secondary outcome, pentamidine safety, was evaluated by
adverse events leading to pentamidine discontinuation.
Results: Total of 285 HSCT patients received at least one dose
of IV pentamidine and were included in the ﬁnal analyses.
Median age of patients was 5 years (range: 0.2 to 32 years).
Patients were on pentamidine prophylaxis for a median of 5
months (range 1-44 months). Only 1 patient developed
breakthrough PCP infection while receiving IV pentamidine
prophylaxis (0.35%). Two patients were diagnosed with
toxoplasmosis while receiving pentamidine prophylaxis
(0.7%). Twenty patients (7%) experienced an adverse event
leading to discontinuation of pentamidine, with tachycardia
being the most common adverse event leading to discon-
tinuation of pentamidine. The rate of adverse effects seen
with pentamidine is comparable to that seen in patients
receiving SMX/TMP prophylaxis which is associated with
adverse effects ranging from 3.1-59%.
Conclusion: In a three year time span only 1 patient
(0.35%) receiving IV pentamidine prophylaxis had a
breakthrough PCP infection. Although SMX/TMP is
considered ﬁrst line for PCP prophylaxis, based on the
results of this study, IV pentamidine should be considered
a safe and effective alternative in pediatric HSCT patients.
Of note, pentamidine does not provide toxoplasmosis
suppression, a consideration for children considered at
high risk of reactivation.547
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Background: Stem cell transplant patients who are hepatitis
B negative at the time of transplant and receive stem cells
from a hepatitis positive donor have a higher risk of liver
related post-transplant complications and hepatitis viral
positivity. The use of lamivudine has been documented in the
literature as chemoprophylaxis for preventing viral reac-
tivation in positive patients and also surface antigen negative
patients receiving stem cell product from hepatitis positive
donors. The expected duration of chemoprophylaxis with
lamivudine therapy is multiple months following stem cell
transplant. This is a case series of using a two dose course of
hepatitis B immune globulin, without lamivudine, for the
prevention of viral seroconversion in stem cell transplant
recipients.
Methods: This is a single center retrospective chart review of
three pediatric stem cell transplant patients who were pre-
scribed hepatitis B immune globulin for prophylaxis of
seroconversion of hepatitis B. Hepatitis B immune globulin
0.06mL per kilogram was administered as two doses, on day
-1 or day 0, and repeated four weeks later. All patients
received allogeneic transplantation from matched related
donors, found to be positive for hepatitis B prior to stem cell
harvest. Diagnoses for stem cell transplant of the patients
were acute lymphoblastic leukemia, congenital myeloﬁbrosis
and cartilage hair hypoplasia. Patient age ranged from 1 to 17
years.
Results: At median of 20 months follow up (range 12-32
months), no patients were reported to have a positive hep-
atitis B DNA after stem cell transplant. No cases of veno-
occlusive disease of the liver were observed. This small case
series may present an alternative, simpler prophylaxis
regimen that is effective at preventing hepatitis viral trans-
mission during stem cell transplant.548
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Background: High-dose chemotherapy with autologous
hematopoietic stem cell transplantation (auto-HCT) can be
an effective treatment for systemic light chain amyloidosis
(AL). However, signiﬁcant morbidity may occur in AL pa-
tients undergoing peripheral blood stem cell (PBSC) mobili-
zation, especially if they have cardiac or renal involvement.
Reported complications include ﬂuid overload, cardiac ar-
rhythmias, bleeding events, and infections.
Methods: We identiﬁed 101 patients with AL who under-
went PBSC mobilization and collection with ﬁlgrastim at a
dose of 10 mcg/kg/day between 2006 and 2013. Fifteen pa-
tients (15%) also received plerixafor at a dose of 0.16-0.24mg/
kg/day after at least 4 days of ﬁlgrastim. The primary
